All products are independently tested by Janoshik Analytical and shipped same-day from Canada
If you're a man who's tried countless diets, exercise programs, and traditional medications only to watch the scale creep up while your energy plummets, you're not alone
Your healthcare provider will determine if a dosage adjustment is appropriate based on your symptoms and overall health condition
After announcing the state would initiate coverage of GLP-1s to combat obesity in September 2022 as part of their state employee health plan, the state reversed course and in January 2025 announced it was opting to end that coverage beginning July 1, 2025
Case reports and safety reviews have linked Lcarnitine with new seizures or increased seizure frequency in some susceptible individuals
Retatrutide Retatrutide is a triple agonist (GIP/GLP-1/glucagon receptor) currently in late-stage clinical trials that has shown remarkable weight loss results of up to 24% in Phase 2 studies
